Speaker Profile
PhD, CEO, GeneCentric Tx
Biography
Michael Milburn has over 20 years of executive leadership experience in drug and diagnostic companies including GSK, Plexxikon, Sirtris Pharmaceuticals, and Metablolon. A biotechnology innovator, he has published over 150 scientific articles and is an expert in the development and commercialization of drug and diagnostic products. He started his career in structurebased drug discovery and published the first scientific articles on the crystal structures of p21 ras proteins in the active and inactive state. He developed the first structurebased fragment screening technology and chemistry and published the first scientific articles on this drug discovery methodology. At GeneCentric, Michael leads the effort to bring RNA based diagnostics to the forefront of precision medicine and the next generation of companion diagnostics.
Talk
Advancing Precision Medicine with Novel RNA Companion Diagnostics
GeneCentric develops and commercializes novel RNAbased companion diagnostics to augment shortcomings in more traditional diagnostic testing such as DNA alterations or IHC. While DNA variants have been valuable in precision medicine, they only reflect potential oncogenic activation. In contrast, RNA diagnostics can be derived to reflect actual oncogenic activity and therefore more predictive of therapy.
Session Abstract – PMWC 2024 Silicon Valley
Track Chair: Razelle Kurzrock, Medical College of Wisconsin
- PMWC 2024 Award Ceremony:
Luminary Honoree: Catriona Jamieson, UCSD Health
- Keynote: Targeting Cancer Stem Cells in Precision Oncology
- Catriona Jamieson, UCSD Health
- Revolutionizing Clinical Trials: Precision Oncology and Novel Trial Designs (PANEL)
Chair: Razelle Kurzrock, MCW
- Andrea Cercek, Memorial Sloan Kettering
- Apostolia Tsimberidou, MD Anderson
- Ben George, MCW
- Transcriptomics in Precision Oncology: Opportunities and Limitations (PANEL)
Chair: Razelle Kurzrock, MCW
- Andrea Califano, Columbia University
- Charles Perou, University of North Carolina
- Eytan Ruppin, NIH
- Bruce Quinn, Bruce Quinn Assoc LL
- David W. Craig, City of Hope Cancer Center - Legislation Mandating Insurance Coverage for Biomarker Testing
- Kathryn Phillips, UCSF
- Collaborative Frontiers: Transforming Cancer Care Access and Patient Outcomes (PANEL)
Chair: Maggie Rougier-Chapman, Labcorp
- Jennifer Rushton, Baptist Health System San Antonio, TX
- Rebecca Previs, Duke Cancer Institute
- Suzanne Garner, Outcomes4Me
- Taylor Jensen, Labcorp - Exploring the Clinical Utility of Dynamic ctDNA Monitoring
Chair: Lincoln Pasquina, Foundation Medicine
- Hatim Husain, UCSD - Antibody-Drug Conjugates (ADCs): Tracing the Evolution and Forecasting the Future (PANEL)
Chair: Adrian Lee, UPMC
- Sandhya Girish, Gilead
- Neelima Denduluri, Astra Zeneca
- Hope S. Rugo, UCSF - PMWC Showcase
- Michael Milburn, Genecentric Tx
- Robert Cook, Castle Bio
- Mark P. de Souza,SonALAsense, Inc.
- Amrie Grammer, Ampel Biosolutions - NCI Showcase
- Nick Reder, Alpenglow Bio
